Novus Therapeutics has launched a phase 1 pharmacodynamics clinical trial for its promising candidate, OP0201, aimed at treating otitis media—a common middle ear infection. The California-based specialty pharmaceutical company, known for its focus on ENT (ear, nose, and throat) disorders, has begun dosing the first adult patients in the trial, named OP0201-C-001, which is taking […]
Pulmatrix, the Massachusetts-based biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to initiate a phase 2 clinical trial for Pulmazole (PUR1900). This drug candidate is targeted at treating allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. The approval follows a successful review of Pulmatrix’s Investigational New Drug (IND) application by […]
In a significant milestone, Prana Biotechnology, an Australian biotech company, has obtained Orphan Drug designation from the FDA for PBT434, its lead molecule aimed at treating Multiple System Atrophy (MSA), a rare and degenerative neurological disease. This designation offers Prana Biotechnology substantial regulatory advantages, such as seven years of market exclusivity and access to tax […]
Nordic Nanovector has commenced the dosing of the first patient in its Phase 1b clinical trial, dubbed Archer-1, which aims to evaluate the combination of its investigational lymphoma drug Betalutin (177Lu-satetraxetan-lilotomab) with Roche’s rituximab (RTX) as a second-line treatment for follicular lymphoma (2L FL). This trial is a critical step in exploring novel treatments for […]
Oncternal Therapeutics, a leading U.S. oncology company, has announced the dosing of the first patient in a phase 1b trial of its investigational drug cirmtuzumab, used in combination with the standard-of-care chemotherapy drug paclitaxel. This trial marks a significant step in evaluating the potential of cirmtuzumab for treating patients with advanced stages of breast cancer. […]
Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed at evaluating the efficacy of XmAb20717 in treating multiple advanced solid tumors. This marks a significant step in cancer therapy, particularly with the use of bispecific antibodies. The DUET-2 trial […]
Check out results of the late-breaking blood thinner clinical trial of Rivaroxaban, Bayer & Janssen’s oral blood thinner for deep vein thrombosis treatment.
Bayer AG and Janssen Pharmaceuticals, two giants in the pharmaceutical industry, have announced significant findings from their EINSTEIN CHOICE clinical trial, showcasing the effectiveness of Xarelto (rivaroxaban), an oral blood thinner, in substantially reducing the risk of recurrent life-threatening blood clots in vein, known as venous thromboembolism (VTE). Breakthrough in VTE Management The late-breaking study […]
Symic Bio, a California based biopharma focued on matrix biology, is all set to begin the phase 1/2a clinical study named as SHIELD of its peripheral artery disease drug, SB-030.
Symic Bio, a biopharmaceutical company based in California specializing in matrix biology, is set to commence a phase 1/2a clinical study, dubbed SHIELD, for its peripheral artery disease drug, SB-030. The study is scheduled across multiple sites in Australia and New Zealand, enlisting 67 patients with symptomatic peripheral artery disease. Trial Focus and Methodology SHIELD […]
Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for its lung cancer drug candidate, Oncoprex. Conducted at The University of Texas MD Anderson Cancer Center, the trial focuses on the investigational immunogene therapy drug in combination with the tyrosine kinase inhibitor erlotinib (Tarceva), targeting patients with […]
The University of Antwerp in Belgium has initiated an innovative clinical trial aimed at mitigating the cognitive deficits associated with breast cancer treatment, marking a significant advancement in the field. This trial will utilize a video game-based training and assessment tool, scientifically designed by the UK-based My Cognition, which specializes in cognitive health. Addressing Cognitive […]